SLC10A1: Hepatic sodium/bile acid cotransporter
A drug works by acting on something in the body, usually a protein made by one gene. This is a page for each of those targets: the drugs that hit it and the diseases it is tied to.
As a major transporter of conjugated bile salts from plasma into the hepatocyte, it plays a key role in the enterohepatic circulation of bile salts necessary for the solubilization and absorption of dietary fat and fat-soluble vitamins.
- Drugs that act on it: 3
- Approved: 1
- In phases 1 to 3: 2
- Sponsors: 3
Who Is On It, and How Far Along
Every drug ChEMBL records acting on SLC10A1, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Protein or peptide
- Other
The Landscape
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: Bile acid transporter inhibitor.| Bulevirtide | Approved | Gilead Sciences | Protein or peptide | Inhibitor | — | 12 | — |
| Hepalatide | Phase 2 | Shanghai HEP Pharmaceutical Co., Ltd. | Protein or peptide | Inhibitor | — | 1 | — |
| Myrcludex b | Phase 2 | Hepatera Ltd. | Other | Inhibitor | — | 0 | — |
Open Trials
The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 9 in all, from ClinicalTrials.gov.Diseases Most Associated With It
Open Targets association score, 0 to 1; all associations- Hypercholanemia, familial, 2
- 0.71
- Hepatitis D virus infection
- 0.48
- Viral infectious disease
- 0.38
- Hypercholanemia, familial 1
- 0.37
- Hypercholanemia, familial
- 0.37
- Intrahepatic cholestasis of pregnancy
- 0.20
- Self-injurious ideation
- 0.19
- Hepatitis B virus infection
- 0.14
- Chronic hepatitis B virus infection
- 0.10
- Cirrhosis of liver
- 0.08
- Infection
- 0.06
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL5287, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt Q14973, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets